In this interview, Dan Fisher, managing director and practice lead for IPM.ai, explains the use of artificial intelligence for stitching together key medical events that may happen over a rare and specialty disease patient’s lifespan that could predict whether or not a patient could be appropriate for a particular treatment or trial.

The rare disease patient journey can differ dramatically between disease states and individual patients, and the better the distinct patient point of view is understood, the more effective clinical trial recruitment or commercial effectiveness can be in reaching those patients. 

IPM.ai collects data from 300 million patients, which can help brands assess a patient population, accelerate clinical trial recruitment, and optimize commercial outcomes. By relying on real-world health signals derived from claims data, machine learning, and AI, it’s possible to create models that reveal the ideal de-identified patient and their healthcare ecosystem – regardless of their current diagnosis status.

Learn about more use cases for applying patient findings to accelerate commercialization impact.

In this interview, Dan Fisher, managing director and practice lead for IPM.ai, explains the use of artificial intelligence for stitching together key medical events that may happen over a rare and specialty disease patient’s lifespan that could predict whether or not a patient could be appropriate for a particular treatment or trial.
The rare disease patient journey can differ dramatically between disease states and individual patients, and the better the distinct patient point of view is understood, the more effective clinical trial recruitment or commercial effectiveness can be in reaching those patients. 
IPM.ai collects data from 300 million patients, which can help brands assess a patient population, accelerate clinical trial recruitment, and optimize commercial outcomes. By relying on real-world health signals derived from claims data, machine learning, and AI, it’s possible to create models that reveal the ideal de-identified patient and their healthcare ecosystem – regardless of their current diagnosis status.
Learn about more use cases for applying patient findings to accelerate commercialization impact.

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement